CD274 and non-small cell lung carcinoma: With respect to immune checkpoint inhibitor (ICI)-based immunotherapy, evidence from a small cohort study of NSCLC patients (n = 24) treated with anti-PD-L1 indicated that a higher PNI was linked to a longer time to treatment failure and improved OS [16].